Vol 6, No 1 (2009)

The place of b-blocker and diuretic in the Russian guidelines of arterial hypertension 2008
Chazova I.E., Ratova L.G., Chazova I.E., Ratova L.G.
Systemic Hypertension. 2009;6(1):4-11
Endothelium dysfunction at arterial hypertension: focus on nebivolol
Vaulin N.A.
Systemic Hypertension. 2009;6(1):11-14
Up-to date view on ƒ-blocker in treatment of arterial hypertension with heart failure
Gorokhovskaya G.N., Petina M.M., Nikolau E.G., Martynov A.I., Gorohovskaja G.N., Petina M.M., Nikolau E.G., Martynov A.I.
Systemic Hypertension. 2009;6(1):14-17
Ramipril - angiotensin converting enzyme ingibitor with a wide spectrum of therapeutic action
Preobrazhenskiy, D.V., Preobrazhensky D.V., Vyshinskaja I.D., Vyshinskaya I.D.
Systemic Hypertension. 2009;6(1):17-22
Arterial hypertension and treatment of non steroidal anti-inflammatory drugs: advantage amlodipin
Ezhov M.V., Yezhov M.V.
Systemic Hypertension. 2009;6(1):23-26
The role of angiotensin receptor antagonists in treatment of arterial hypertension: focus on losartan
Baryshnikova G.A., Baryshnikova G.A.
Systemic Hypertension. 2009;6(1):26-32
Obstructive sleep apnea syndrome
Litvin A.Y., Chazova I.E., Litvin A.Y., Chazova I.E.
The paper describes the major mechanisms of occurrence of obstructive sleep apnea syndrome (OSAS). Large populationbased randomized studies in this area show the importance and prevalence of obstructive sleep respiratory disorders and provide evidence for their clinical significance in the practice of a therapist and cardiologist. Multiple references demonstrate the specific features of an association of OSAS with cardiovascular diseases, as well as major treatment approaches and methods at the present stage are given. Key words: obstructive sleep apnea syndrome, pathogenesis, epidemiology, diagnosis, clinical picture, treatment, cardiovascular diseases
Systemic Hypertension. 2009;6(1):32-41
Final results of STRATEGYA Study (Russian Comparative Programme on a fixed,low-dose perindopril/indapamide combination efficacy in hypertensive patients with inadequateblood pressure control): use of a fixed, low- dose perindopril/indapamide combination in hypertensivepatients in real clinical practice
Martynyuk T.V., Kolos I.P., Chazova I.E., Martyniuk T.V., Kolos I.P., Chazova I.E.
Aim: to evaluate blood pressure (BP) lowering rates in 3 subgroups of hypertensive patients in 3 different clinical situations in which Noliprel and if necessary Noliprel forte may be recommended. Results. In 4 wks of treatment SBP mean values were significantly reduced from 158±19 mm Hg to 131±11mm Hg (p<0,05), DBP - from 94±8 mm Hg to 81±6 mm Hg (p<0,05). According to BP-monitoring in 16 wks of treatment SBP mean values were significantly reduced from 155±25 mm Hg to 127,5±9,9 mm Hg (p<0,05) in the 1st subgroup; from 157±14 mm Hg to 131,1±11 mm Hg (p<0,05) in the 2d subgroup; from 163±14 mm Hg to 133,7±12 mm Hg (p<0,05) in the 3d subgroup accordingly; DBP mean values were decreased from 93±8 mm Hg to 79,8±5,8 mm Hg (p<0,05) in the 1st subgroup; from 93,6±8,2 mm Hg to 81,3±6,48 mm Hg (p<0,05) in the 2d subgroup; from 94,8±8,3 mm Hg to 82,6±7,1 mm Hg (p<0,05) in the 3d subgroup accordingly. The treatment with Noliprel/ Noliprel forte was equally efficacious in men and women of different age groups, in hypertensive pts both normal and increased body mass as well as in pts with obesity of Grade 1. 96% of pts noticed excellent and very good tolerability of Noliprel/ Noliprel forte treatment. After completing the study the medication was recommended for further treatment for 96% of pts. Conclusions. Noliprel/Noliprel forte treatment results in the achievement of goal BP levels in the majority of pts with inadequate BP control in different clinical situations. There was noticed an equal antihypertensive effects in young and old pts, in men and women, in pts with normal and increased body mass as well as in pts with Grade 1 obesity. Noliprel/Noliprel forte treatment is characterized by excellent tolerability.
Systemic Hypertension. 2009;6(1):42-49
Metabolic syndrome
Mychka V.B., Chazova I.E., Mychka V.B., Chazova I.E.
Systemic Hypertension. 2009;6(1):50-53
Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients withtype 2 diabetes mellitus and mild hypertension:a sequential, randomized, double-blind clinical trial
Giuseppe Derosa -., Arrigo FG Cicero -., Angela D'Angelo -., Elena Fogari -., Sibilla Salvadeo -., Alessia Gravina -., Ilaria Ferrari -., Raffaella Fassi -., Roberto Fogari -.
Systemic Hypertension. 2009;6(1):54-58
Possible combinations of antihypertensive drugs at treatment of arterial hypertension at patientswith metabolic syndrome
Mychka V.B., Chazova I.E., Mychka V.B., Chazova I.E.
Systemic Hypertension. 2009;6(1):58-64
Clinical case: Effectiveness of combined therapyOrlistat and Irbesartan at the Metabolic syndrome patient with Arterial hypertension
Ivanov K.P., Mychka V.B., Kirillova M.Y., Chazova I.E., Ivanov K.P., Mychka V.B., Kirillov M.J., Chazova I.E.
Systemic Hypertension. 2009;6(1):64-66
Hyperfiltration and metabolic syndrome
Arutyunov G.P., Oganezova L.G., Arutyunov G.P., Oganezova L.G.
Systemic Hypertension. 2009;6(1):66-70
Renovaskulyarnaya arterial'naya gipertenziya: diagnostika i lechenie
Danilov N.M., Chazova I.E., Savchenko A.P.
Systemic Hypertension. 2009;6(1):71-73
Functional state of retina - criterion of efficacy antihypertensive therapy
Adasheva T.V., Zadionchenko V.S., Shamshinova A.M., Arakelyan M.A., Adasheva T.V., Zadionchenko V.S., Shamshinova A.M., Arakelian M.A.
Systemic Hypertension. 2009;6(1):74-80

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies